Despite the favourable reaction to the announcement of the Bach Biosciences agreement (stock up 35%), Avacta’s market capitalisation is still much lower than biotech peers that have unique protein-based platforms and drug candidates in the clinical stage, where Avacta is on track to be by 2020.Full report is available via Capital Network website
OptiBiotix Health Plc (LON:OPTI) focuses on managing and treating widespread, chronic medical conditions, such as obesity and high cholesterol, through the modulation of the human microbiome.
- Key inflection point: topline data readout from the PhaseOut DMD phase 2 trial in Duchenne (DMD) expected in 3Q 2018
- Imminent start of a pivotal phase 3 study for ridinilazole in C. difficile infections (CDI)
- Recent Discuva acquisition reinforces novel antibiotics discovery capabilities
- Current valuation (market cap of c. $165 mln) undemanding given the stage and commercial potential of Summit's lead programs
Over the last year or so, management has delivered significant progress in bringing their Affimer platform into to the commercial stage, across both therapeutics and diagnostic applications.